Astellas Pharma Inc
TSE:4503
Astellas Pharma Inc
Operating Income
Astellas Pharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Astellas Pharma Inc
TSE:4503
|
Operating Income
¥142B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
3%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥464.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥188B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥294.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
32%
|
CAGR 10-Years
3%
|
|
Eisai Co Ltd
TSE:4523
|
Operating Income
¥65.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥444.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
See Also
What is Astellas Pharma Inc's Operating Income?
Operating Income
142B
JPY
Based on the financial report for Dec 31, 2023, Astellas Pharma Inc's Operating Income amounts to 142B JPY.
What is Astellas Pharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
3%
Over the last year, the Operating Income growth was -36%. The average annual Operating Income growth rates for Astellas Pharma Inc have been -5% over the past three years , -12% over the past five years , and 3% over the past ten years .